Image pharmaphorum Editor Digital Targeted agents and immunotherapies Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment. Patients Putting patient perspectives at the heart of kidney cancer r... Commissioned by Ipsen. Digital An open call for innovation There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains. Digital Understanding the prevention and treatment needs for cardiov... What does the current picture of cardiovascular disease in Europe look like? Load more results
Digital Targeted agents and immunotherapies Targeted agents and immunotherapies are two of the most promising areas for significant advancements in cancer treatment.
Digital An open call for innovation There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
Digital Understanding the prevention and treatment needs for cardiov... What does the current picture of cardiovascular disease in Europe look like?
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.